Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes who had a body-mass index (BMI) of 30 or higher or a BMI of 27 or higher with at least one obesity-related complication. Participants were randomly assigned to receive the combination of semaglutide 2.4 mg and cagrilintide 2.4 mg (CagriSema) or placebo. The estimated mean change in body weight from baseline to week 68 was -20.4% with CagriSema compared to -3.0% with placebo. Gastrointestinal adverse events occurred in 79.6% in the CagriSema group vs 39.9% in the placebo group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cagrilintide 2•4 mg/week; semaglutide 2•4 mg/week for 68 weeks 17•3% (16•6-18•1) vs placebo; 5•5% (4•3-6•7) vs semaglutide alone 0•4% (not more than the effect of semaglutide alone) Improved physical function (based on IWQOL-Lite-CT and SF-36v2 scores); drug discontinuation due to adverse events 5•9%; weight plateau not reached Garvey et al (2025) 135”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [135]
In the citing paper
“In adults with overweight or obesity, cagrilintide-semaglutide reduced bodyweight by 17•3% (16•6-18•1; placebo-subtracted), 135 along with reductions in waist circumference, blood pressure, and improved physical functioning scores.135”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [135]
In the citing paper
“Gastrointestinal adverse events were slightly more frequent with CagriSema than with semaglutide alone.135”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [135]
In the citing paper
“The effects of the drug combination were greater than the effects of either medication alone, but less than the sum of effects for both medications.135”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [135]
In the citing paper
“In the REDEFINE 1 trial, coadministration of cagrilintide 2.4 mg (a long-acting amylin analog) and semaglutide 2.4 mg (CagriSema) resulted in a 20.4% mean Weight loss at 68 weeks in adults with overweight or obesity.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [78]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citation2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s002 · Cited by 1,393
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Self-citationWeight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Cited by
Items 101–200 of 217
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies
Bijoch, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145358 · Cited by 6
“…amylin analogue cagrilintide and its semaglutide combination CagriSema (with weight loss of approximately 15.7–22.7% across the REDEFINE programme) [16,17], and the unimolecular GLP-1/amylin agent amycretin each engage receptor systems—glucagon, GIP antagonism, and amylin/calcitonin…”
InfluentialXie, J., Yang, Y., Chen, W., (45927), L. W., Weng, S., Lyu, Q., & Cao, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00722-7 · Cited by 1
“…of cagrilintide and semaglutide, achieved an average weight loss of 20.4% after 68 weeks in obese patients without diabetes, demonstrating superior efficacy compared to either agent alone and positioning it as a potential next-generation drug with significant commercial therapeutic value [183].”
InfluentialAmylin at the crossroads of type 2 diabetes and neurodegenerative diseases
Castillo, I. L. D., Garcia-Martin, J., Gutiérrez, A., & Moreno‐González, I. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103226 · Cited by 1
Gadelmawla, A. F., Hammad, N., Atta, K., Diaa, A., Abouzkaly, F., Soni, K., Kelkar, R., Agrawal, S. P., Ahmed, R., Jain, H., et al. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.030 · Cited by 4
Navigating the benefits and harms of GLP-1 and GLP-1/GIP agonists in obesity
O'Connor, R. G. (2026) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2025.000039 · Cited by 2
“41 This level of lM loss has been equated to a decade of human ageing.”
Busk‐Cirera, L., Carlsen, I. Ø., Madsen, L. B., Sandsdal, R. M., Jensen, E., Jensen, S. B. K., & Torekov, S. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71006 · Cited by 6
“Garvey 2025 (REDEFINE-1), Look 2025 (SURMOUNT-1), and Wilding 2021 (STEP-1) were double-blind, placebo-controlled phase 3 trials [20, 21, 45].”
InfluentialObesity, Visceral Adiposity, and the Future of Hypertension Treatment
Gallagher, B. D. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf175 · Cited by 1
Nicoletti, C. F., Lara, F. V.-O. D., & Martinez, J. A. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100690 · Cited by 2
Amylin: A Multi‐Functional Pancreatic Hormone—A Review
Foll, C. L., & Lutz, T. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71146 · Cited by 1
Peary, A., Vaidya, N., Jakicic, J., & Chao, A. M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01426-y · Cited by 1
Endogenous Incretin Insufficiency in Obesity: Etiological Defect or Metabolic Maladaptation?Preprint
Andrade, L. J. D. O., de Oliveira, G. C. M., Bittencourt, A. M. V., Salles, O. J. D. M., & de Oliveira, L. M. (2026) · Research Square · doi:10.21203/rs.3.rs-9453154/v1
Ciarloni, A., Salvio, G., Bordoni, M., Giacchetti, G., & Balercia, G. (2026) · Biomedicines · doi:10.3390/biomedicines14040778
Petrelintide and the evolving role of amylin agonism in obesity
Madsbad, S., & Holst, J. J. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00216-0
Palka, W., Moćko, P., Śladowska, K., Holko, P., & Kawalec, P. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03006-y
Você atingiu sua meta de perda de peso com as canetas GLP-1 – e agora?
Sheer, A. (2026) · The Conversation · doi:10.64628/ade.wcfmnx3wn
The ‘astounding’ rise of semaglutide — and what’s next for weight-loss drugs
Nogrady, B. (2026) · Nature · doi:10.1038/d41586-026-00228-1
Busetto, L., Contreras, C. O., Christensen, M. H., Garvey, T., Horn, D. B., McGowan, B. M., Miller, C. P., Schnecke, V., & le Roux, C. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71134
Obesity: a disease of the ponderostat and the regulation of energy balance
Buscemi, S., Buscemi, C., Colombrita, P., Randazzo, C., Barile, A. M., & Arnaldi, G. (2025) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-025-01790-9 · Cited by 2
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
Metabolic advances in 2025: from clinical breakthroughs to molecular reprogramming
Dalamaga, Μ., & Liu, J. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100442 · Cited by 2
Wilkinson, M. J., Padilla, E., Wang, Y., Raygani, S., Manoogian, E. N. C., Laing, K. L., Tong, K., Liu, L., Van, D. T., Nguyen, J. P., et al. (2026) · Obesity · doi:10.1002/oby.70228 · Cited by 2
Lim, S. K., Hwang, Y., Son, J. W., Lee, S., Jung, C. H., Kim, H., Lim, H., Park, S., Kim, J., Youn, J., et al. (2026) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2026.6.e26
Fortin, S. M., Sanchez-Navarro, M. J., Hu, J., Zhou, M., Zhang, C., Petticord, M. C., Alonso, B., Cohen, S. A., & Hayes, M. R. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102427
Nong, K., Shi, Q., Xie, X., Wang, Y., Agarwal, A., Guyatt, G. H., Zhang, H., Gao, Y., Khunti, K., le Roux, C. W., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5347782
Tirzepatide in type 1 diabetes: beyond mere weight loss
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2685653
Hypothalamus-liver talks: whispers in the language of metabolism
Ferreira, V., Fernández-González, I., Vattathara, J. J., Rodríguez-Díaz, A., Fernández-Sanmartín, P., & Diéguez, C. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10031-y
(2026) · doi:10.1016/j.tem.2026.03.002
Kunicki, M., Katulska, Z., Wolert, W., & Kunicka, A. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109025
Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome
Shahd, A., Bridges, N., & Goldstone, A. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1881392 · Cited by 1
Eloralintid als neuer Amylinrezeptoragonist zum Gewichtsmanagement
Schürfeld, R. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01404-z
Han, W., Shepherd, P. R., Ueki, K., Li, J., Xu, A., Oh, G., & Kim, J. B. (2026) · Molecules and Cells · doi:10.1016/j.mocell.2026.100364
Investigating fasting for metabolic health and longevity
Steinhauser, M. L., & Fazeli, P. K. (2026) · Biogerontology · doi:10.1007/s10522-026-10438-9
Feraco, A., Camajani, E., Muscogiuri, G., Barrea, L., Colao, A., & Caprio, M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00695-7 · Cited by 2
You’ve reached your weight loss goal on GLP-1 medications – what now?
Sheer, A. (2026) · The Conversation · doi:10.64628/aai.uve5sfkhv
Beyond Percentage of Weight Lost — Protecting Participants in Obesity Trials
Schmitz, S. H. (2026) · New England Journal of Medicine · doi:10.1056/nejmp2609407
Butt, S. P., Abdulaziz, S., Razzaq, N., Anand, R., Srivatav, N., Saleem, Y., Lender, O., Griffin, M., Afzal, A., Kakar, V., et al. (2026) · Journal of ExtraCorporeal Technology · doi:10.1051/ject/2026021
Chen, D., Ma, B., Sun, H., Zhang, J., Gong, L., Wang, W., Liu, Z., Zha, H., Du, S., Chen, M., et al. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2026-003026 · Cited by 1
Martínez‐Corral, I., Monaco, N., Brierley, D. I., & Imbernón, M. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70636 · Cited by 1
Lan, L., Ni, Y.-N., Zhou, Y., & Luo, F. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1709205 · Cited by 1
Krzystek, Ł., Buć, K., Buć, P., Mazurek, M., Józefczyk, J., Zieliński, K., Ganczar, K., Jurkowski, S., Rudzińska, M., & Zalewski, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4388
Koehestanie, P., & Gerdes, V. E. A. (2026) · Endoscopy · doi:10.1055/a-2901-5022
Ahmed, M. (2025) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.52.68.79
Anti-Obesity Drugs: The Rising Significance of GLP-1Agonist, Tirzepatide
Agrawal, P. K., & Garg, R. (2026) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_259_25
Impact of glucagon-like peptide-1 receptor agonists on bone metabolism
Vadini, V., Duan, D., & Moseley, K. F. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag323 · Cited by 2
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care
Wojeck, B. S., & Nokes, B. T. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101038
Vikash, F., Ehsan, M., Valencia, S. O., Nadeem, A., Moazzam, E., Butsch, W. S., & Garg, S. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70180
Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs
Fischer, S. L., & Borner, T. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108382
Petersen, J., Merrild, C., Holm, S. K., Kurgan, N., Hassan, S., Mathiesen, C. V., Börchers, S., Svendsen, C., D’Anna, S., Andersen, N. R., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01603-y
Retatrutide in type 2 diabetes mellitus and obesity: an overview
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2642415
Anti-Obesity Medications in Longevity and Aesthetic Medicine
Bijoch, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15156026
Malviya, V. (2026) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2026.00050
What REDEFINE 5 signals for obesity trials in Asia and beyond
Kang, Y. M., & Aroda, V. R. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00012-4
Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review
Zhou, J., Zhang, N., Li, J., Qin, X., Kong, L., Bai, L., & Han, T. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101481
Garvey, W. T., Ard, J. D., Connery, L. E., Frías, J. P., le Roux, C. W., Pietiläinen, K. H., DINESEN, M., Hagen, B. F., Larsen, L., Hesse, D., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00213-5 · Cited by 2
Self-citationDalt, L. D., Olmastroni, E., Scotti, S., D’Ardes, D., Bianconi, V., D’Onofrio, L., Gioia, L. D., Visco, V., Bencivenga, L., Salis, F., et al. (2026) · European Atherosclerosis Journal · doi:10.56095/eaj.v5i1.135
Diabetes Update 2026 – Neue Studienergebnisse und Erkenntnisse
Scherbaum, W. A. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01486-3
Combined amylin analogue and GLP1 receptor agonist therapies are highly promising for weight loss
Tysoe, O. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01156-2 · Cited by 2
Piguet, C. E. M., Nucci, R., & Beaudry, J. L. (2026) · The Journal of Physiology · doi:10.1113/jp291081 · Cited by 1
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Sztanek, F., Lőrincz, H., Harangi, M., & Nagy, A. C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71277 · Cited by 1
Pharmacological management of obesity: Current landscape and emerging therapies
Atal, S., Agrawal, C., Gupta, R., & Sadasivam, B. (2026) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_37_26
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo
Yaseen, M., Ameer, A., Ali, Z., Jamali, J. A., Kumar, A., Siddiqui, M. B. A., Kumari, P., Hassaan, M., Nanwani, P., Basit, M. A., et al. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005353
Cho, D. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0002
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
Eisa, N., & Barood, O. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.018 · Cited by 3
Khan, B. W., Agha, S. A., Qamar, I., Khattak, M. H., Rehman, A., Qazi, T. I., Siddiqui, S. A., Zeeshan, N., Khan, U. Z., Bibi, H., et al. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05809-5
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
Effect of GLP‐1 receptor agonist on nutrient intake: A narrative review
Fujioka, K. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70172
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Self-citationLi, M., Zhang, J., Yang, Y., Tian, S., Cheng, X., Li, Q., Li, P., Zhou, S., Shen, H., Liu, Z., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-337802
Xu, R., Chang, Y., Su, E., Wang, Y., Zhang, Y., Ma, X., Han, X., & Zhu, R. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1853598
DeCoster, M., & Narla, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.09.003 · Cited by 1
Obesity and Cardiovascular Diseases: CVIA State-of-the-Art Review
Liu, N., Pan, Y., Liu, F., Mei, J., Zhang, X., Zhang, R., Zhang, S., Luo, F., Wu, Y., Gong, Y., et al. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2026.0010 · Cited by 1
Rasool, Z. K., Shah, R., Batool, A. E. Z., Shah, R., Khachatryan, M., Bhardwaj, S., Ali, A., Atta, M., Bakthavatchalam, P., Khawar, M. M. H., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1903335 · Cited by 1
Mehetre, K. N., & Dawane, J. S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933913
DeCoster, M., & Narla, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.08.013
RetractedMarassi, M., Pollis, R. M., & Fadini, G. P. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104714
Chen, J. J., Chiru, E.-D., & Shen, S. (2026) · Current Breast Cancer Reports · doi:10.1007/s12609-026-00662-0
Kamrul-Hasan, A. B. M., Khalil, I., Mahajan, K., Dutta, D., Banerjee, M., & Pappachan, J. M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70247 · Cited by 1
Gao, S., & Borner, T. (2026) · Appetite · doi:10.1016/j.appet.2026.108723 · Cited by 2
Cellular loci for cagrilintide action identified
Hevesi, Z., & Harkany, T. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01541-9
Nielsen, M. J. F., Becker, N., Duus, H. H. H., Kirkeby, K., Kupčová, V., Lauenborg, B. W., Low, B., Svolgaard, O., & Witten, L. (2026) · Clinical Pharmacokinetics · doi:10.1007/s40262-026-01654-0 · Cited by 3
Is pharmacotherapy ready to redefine the state of the art in obstructive sleep apnea care?
Johnston, E. K., Bird, E. M., Malhotra, A., & Harding, C. D. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2634201
Gulisano, W., Ter-Borch, G., Brown, P., Feinberg, J. B., Gonczi, M., Hildebrand, E., Legere-DeJohn, G., Sustarsic, R. K., & Sparre, T. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261461530
Peripheral targets for neuropathic pain
Afsharipour, A., Ciotu, C. I., Resch, F. J., & Fischer, M. J. M. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70553
Moiz, A., Filion, K. B., Samuels, A. E., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05519
Weekly Journal Scan: REDEFINing the next generation of obesity pharmacotherapy
Liuzzo, G., & Patrono, C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf628
Miličević, T., Cvitković, I., Volčanšek, Š., Katsiki, N., Mikhailidis, D. P., Patoulias, D., & Muzurović, E. M. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2706660
Bariatric surgery in the era of modern obesity pharmacotherapy
Zhao, A. Y., & Dash, S. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjag004
Robinson, R., Sarkar, T. D., Moore, S., & Malhotra, A. (2026) · Current Sleep Medicine Reports · doi:10.1007/s40675-026-00373-z
Wang, X., Wang, W., Han, F., Li, T., Kang, W., Yang, X., Wang, J., & Yang, L. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01505-y
A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy
Lee, S. M., Song, H., & Kwon, Y. O.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19071047
Oh, J., & Choi, J. H. (2026) · Pharmaceuticals · doi:10.3390/ph19091361
ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES
Wielogórska, A., Stasiak, O., Kowalik, F., & Deczkowska, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5972
Monnier, L., Schlienger, J.-L., & Colette, C. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.002
Selective amylin receptor agonism: promise beyond incretins
van Beek, A. P. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02214-7
Metadata
- Authors
- Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., & Wilding, J. P. H.
- Affiliations
- University of Alabama at Birmingham (US)
- Helmholtz Munich (DE)
- Novo Nordisk, Søborg, Denmark
- University of Leicester (GB)
- University of Helsinki (FI)
- Washington Center for Weight Management and Research (US)
- University of Rome Tor Vergata (IT)
- University of Pennsylvania (US)
- Novo Nordisk (Denmark) (DK)
- University of Liverpool (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-08-14
- Volume
- 393
- Issue
- 7
- Pages
- 635-647
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4411522078
- Semantic Scholar
- 88a7f366045169f809d813a8da85f107c6d472ed
- Cited by
- 238
- References
- 32
- Citations by year
- 2026: 181 · 2025: 57
- FWCI
- 133.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- cagrilintide, semaglutide, combination therapy, obesity, overweight, weight loss, GLP-1 receptor agonists, GIP receptor agonist, obesity-related comorbidities, lifestyle intervention, treatment policy estimand, cardiovascular outcomes, GIP/GLP-1 receptor agonist
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Double-Blind Method, Drug Combinations, Female, Humans, Hypertension, Male, Middle Aged, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Anti-Obesity Agents, Dyslipidemias, Overweight, Glucagon-Like Peptide 1, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.